Enhancing effect of bevacizumab in the classic bleomycin, etoposide, cisplatin treatment applied in human testicular germ cell tumors

Abstract

Purpose: This study aimed to evaluate the therapeutic potential of Bevacizumab, a vascular endothelial growth factor (VEGF) inhibitor, in combination with the standard Bleomycin, Etoposide, and Cisplatin (BEP) regimen for the treatment of testicular germ cell tumors (TGCTs). The primary focus was to investigate its ability to enhance treatment efficacy while reducing cytotoxic side effects. Materials and Methods: The half-maximal inhibitory concentration (IC50) of the BEP regimen was determined in the 1618-K human TGCT cell line and subsequently combined with varying concentrations of Bevacizumab. Cell viability was assessed using the 3-(4,5-dimethylthiazolwere analyzed by immunohistochemistry. Results: Bevacizumab significantly reduced cell viability in (2.05 +/- 1.04) was significantly lower than in the control mechanisms. through in vivo studies.